These results also suggest that the inhibition of glycosylation could be a promising metabolic strategy to reduce T cell inhibitory signaling through PD-L1/PD-1 axis in the context of anti-tumor immune response without excessively suppressing T-cell activation and effector functions, but further work will be needed to confirm this. This evidence concerns the gene CD274 and neoplasm.